1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

4,615.30
INR
+61.50
(+1.35%)
61.79EPS
73.91P/E
1.56TMarket Cap
Oct 23Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
119.14
135.29
192.63
167.59
172.11
220.47
229.87
233.01
248.75
279.62
312.08
334.39
406.36
443.11
Basic EPS, GAAP
19.62
22.19
51.21
27.58
20.04
12.89
30.28
36.99
22.96
36.79
48.94
56.47
63.92
62.51
Free Cash Flow per Basic Share
5.89
16.77
63.32
15.42
3.04
33.54
29.14
49.35
47.29
53.01
83.72
58.3
69.3
- -
Dividend per Share
7.9
5.9
24.81
6.02
7.82
9.15
21.23
10
20
25.5
30
32
38.08
- -
Book Value per Share
56.21
78.09
103.24
128.53
136.57
139.59
142.51
172.47
175.89
183.13
202.58
224.28
247.85
- -
Tangible Book Value per Share
55.37
21.63
47.58
73.17
-30.71
-10.65
3.19
44.63
63.45
22.78
57.18
88.3
-592.85
- -
Basic Weighted Avg Shares
338
338
338
338
338
338
338
338
338
338
338
338
338
349
Sales/Revenue/Turnover
40,323
45,788
65,194
56,722
58,248
74,618
77,800
78,862
84,188
94,637
105,623
113,173
137,530
154,600
Operating Margin (%)
23.62
18.11
38.82
19.11
16.15
18.34
19.52
23.11
21.02
22.61
24.35
25.85
25.01
23.8
Depreciation Expense
870
1,907
2,376
3,069
4,086
6,177
6,544
6,573
6,619
7,020
7,953
7,949
11,189
15,110
Net Income, GAAP
6,639
7,509
17,332
9,336
6,781
4,363
10,247
12,519
7,772
12,452
16,564
19,113
21,634
21,810
Effective Tax Rate (%)
21.34
20.09
26.04
14.2
27.16
22.32
13.64
17.98
36.6
32.59
29.58
28.49
25.56
24.8
Profit Margin (%)
16.46
16.4
26.59
16.46
11.64
5.85
13.17
15.87
9.23
13.16
15.68
16.89
15.73
14.11
Working Capital
12,299
13,938
14,027
21,411
602
-1,278
-4,751
6,299
7,499
-1,336
1,862
9,054
10,486
- -
LT Debt
7,445
21,729
18,501
22,408
41,115
39,129
33,039
29,633
21,600
25,492
16,682
13,376
118,412
- -
Total Equity
19,028
26,434
34,946
43,506
46,227
47,244
48,232
58,372
59,530
61,981
68,562
75,907
175,848
- -
Return on Invested Capital (%)
29.26
15.88
30.78
14.38
7.62
7.15
12.18
13.95
7.83
13.44
16.48
18.95
11.52
- -
Return on Capital (%)
26.83
20.83
33.32
17.43
10.03
7.56
13.18
14.41
9.04
13.61
16.97
19.3
11.4
- -
Return on Common Equity (%)
39.94
33.04
56.48
23.8
15.12
9.34
21.47
23.49
13.18
20.5
25.38
26.46
27.08
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
31,843
- -
LT Borrowings
- -
116,512
- -
LT Finance Leases
- -
1,901
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
338
338
338
Market Capitalization
1,303,015
1,428,307
1,563,652

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
93,919
- -
Cash, Cash Equivalents & STI
- -
23,552
- -
Accounts Receivable, Net
- -
30,309
- -
Inventories
- -
31,382
- -
Total Current Liabilities
- -
83,433
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
31,843
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.52%
31.82%
131.66%
Free Cash Flow
95.79%
10.87%
18.86%
Net Income, GAAP
13.18%
16.78%
13.19%
Sales/Revenue/Turnover
8.29%
11.89%
21.52%
Total Cash Common Dividend
22.12%
34.17%
19.01%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
28,150
28,310
27,620
29,090
113,173
2026
31,280
32,460
32,510
41,280
137,530
2027
48,350
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
13.51
13.37
14.88
14.71
56.47
2026
16.19
17.45
18.77
11.51
63.92
2027
14.87
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
32
2026
- -
- -
- -
- -
38.08
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Aman Samir Mehta
Full Time Employees
20,341
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Avirat, Thaltej Shilaj Road Ahmedabad GU India 380059
IPO Date
Nov 3, 1994
Website
torrentpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Limited (TORNTPHARM.NS), the flagship company of Torrent Group founded in 1959 and headquartered in Ahmedabad, India, manufactures and markets a broad portfolio of branded and generic pharmaceutical formulations across key therapeutic segments including cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infectives, pain management, women's healthcare, vitamins minerals and nutrients, oncology, nephrology, pulmonology, gynecology, and pediatrics; it offers finished dosage forms such as tablets, capsules, semi-solids including creams gels ointments and lotions, alongside active pharmaceutical ingredients and contract manufacturing services. The company pioneered niche marketing in India and maintains leading positions in cardiovascular and central nervous system therapies, with significant presence in over 50 countries encompassing the US, EU including Germany and UK, Brazil, and emerging markets through wholly-owned subsidiaries in 15 countries. In recent developments, Torrent Pharmaceuticals Limited secured Competition Commission of India approval in October 2025 for its acquisition of a controlling 46.4% stake in J.B. Chemicals & Pharmaceuticals Limited from KKR at an equity valuation of approximately INR 25,689 crores, to be followed by an open offer and merger that will enhance its branded generics portfolio in ophthalmology, IVF, nephrology, and anti-parasitics while providing entry into the high-margin contract development and manufacturing organization business; it has also pursued strategic US manufacturing expansions, chronic therapy innovations, and partnerships such as with Novartis for cardiovascular drugs like inclisiran.